Hu S, Dutt J, Zhao T, Foster C S
Hilles Immunology, Laboratory, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, MA, 02114, USA.
Ocul Immunol Inflamm. 1997 Sep;5(3):173-80. doi: 10.3109/09273949709116892.
This study investigated the effect of tetrandrine (TDR) on experimental herpes simplex keratitis (HSK) in mice. BALB/c mice were divided as follows: Group 1, untreated; Group 2, acyclovir (ACV)-treated from day 0 postinfection; Group 3, ACV-treated from day 7; Group 4, TDR-treated from day 0; and Group 5, TDR-treated from day 7. All mice were infected in the right cornea with herpes simplex virus (HSV) type I. TDR 30 mg/kg and ACV 120 mg/kg were administered intraperitoneally daily. The mice were observed for 14 days postinfection. Clinical inflammatory reactions and ocular histopathology were analyzed. The herpes specific antibody response and the delayed type hypersensitivity (DTH) response were studied. Of the 22 untreated mice, 16 developed HSK (incidence, 72.7%). TDR given from day 7 reduced the HSK incidence to 8.5% (p < 0.01); the incidence of HSK was 45.4% in mice treated with TDR from day 0 (p > 0.05). Systemic ACV given from day 0 inhibited HSK development (p < 0.01); ACV given from day 7 resulted in an HSK incidence of 50% (p > 0.05). The specific anti-HSV antibody response in the serum of mice treated with TDR or ACV either from day 0 or day 7 was significantly less than that of untreated mice (p < 0.01 and p < 0.05, respectively), and TDR treatment suppressed DTH responses to HSV (p < 0.05). Systemic TDR administered after HSV inoculation of the cornea significantly modulates murine HSK development at least partly by modifying the host immune/inflammatory response to the virus.
本研究调查了粉防己碱（TDR）对小鼠实验性单纯疱疹性角膜炎（HSK）的影响。将BALB/c小鼠分为以下几组：第1组，未治疗；第2组，感染后第0天开始用阿昔洛韦（ACV）治疗；第3组，感染后第7天开始用ACV治疗；第4组，感染后第0天开始用TDR治疗；第5组，感染后第7天开始用TDR治疗。所有小鼠右眼角膜均感染I型单纯疱疹病毒（HSV）。每天腹腔注射TDR 30 mg/kg和ACV 120 mg/kg。感染后观察小鼠14天。分析临床炎症反应和眼部组织病理学。研究疱疹特异性抗体反应和迟发型超敏反应（DTH）。22只未治疗的小鼠中，16只发生HSK（发病率72.7%）。感染后第7天给予TDR可将HSK发病率降至8.5%（p<0.01）；感染后第0天开始用TDR治疗的小鼠HSK发病率为45.4%（p>0.05）。感染后第0天给予全身性ACV可抑制HSK发展（p<0.01）；感染后第7天给予ACV导致HSK发病率为50%（p>0.05）。感染后第0天或第7天用TDR或ACV治疗的小鼠血清中特异性抗HSV抗体反应明显低于未治疗的小鼠（分别为p<0.01和p<0.05），且TDR治疗可抑制对HSV的DTH反应（p<0.05）。角膜接种HSV后给予全身性TDR至少部分通过改变宿主对病毒的免疫/炎症反应，显著调节小鼠HSK的发展。
